Composition for improving skin sagging containing compound k

The composition with Compound K addresses skin sagging by increasing Col7A1 and Col17A1 expression to strengthen the DEJ, improving the epidermal-dermal connection and reducing skin drooping.

KR103047863B1Active Publication Date: 2026-11-11AMOREPACIFIC CORP
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
KR1020240045899
Authority / Receiving Office
KR · KR
Patent Type
Patents
Current Assignee / Owner
Filing Date
2024-04-04
Publication Date
2026-11-11
Estimated Expiration
2044-04-04

AI Technical Summary

Technical Problem

Existing compositions fail to effectively improve skin sagging caused by damage to the dermoepidermal junction (DEJ) due to aging, which weakens the connection between the epidermis and dermis, leading to structural changes and reduced skin elasticity.

Method used

A composition containing Compound K is used to enhance the expression of Col7A1 and Col17A1 proteins, which strengthen the DEJ function by increasing the binding strength between the epidermal and dermal layers.

Benefits of technology

Compound K effectively improves skin sagging by restoring the DEJ function, enhancing the bonding strength between the epidermal and dermal layers, and firming the boundary between them, thereby preventing and reducing skin drooping.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 112024037603391-PAT00002_ABST
    Figure 112024037603391-PAT00002_ABST
Patent Text Reader

Abstract

The present disclosure relates to a composition for improving skin sagging containing Compound K. Specifically, the composition for improving skin sagging according to the present disclosure can effectively improve skin sagging caused by damage to DEJ function due to aging by increasing the expression of Col7A1 and Col17A1, which are proteins constituting the DEJ (dermoepidermal junction) connecting the epidermal layer and the dermal layer, thereby enhancing the DEJ function and improving the binding strength between the epidermal layer and the dermal layer and hardening the boundary between the epidermal layer and the dermal layer.
Need to check novelty before this filing date? Find Prior Art

Description

Technology Field

[0001] The present disclosure relates to a composition for improving skin sagging containing Compound K. Background Technology

[0002] As skin tissue ages, inflammatory responses increase, and external stimuli such as UVB, fine dust, and blue light (high-energy visible light) are known to induce skin aging. These external stimuli are believed to further accelerate the reactions that occur due to natural aging. Due to inflammatory aging and external stimuli, the skin's barrier function is damaged and it loses elasticity; in particular, skin sagging intensifies as the dermoepidermal junction (DEJ), which connects the epidermal and dermal layers, is damaged.

[0003] Therefore, in order to improve skin sagging, it is necessary to strengthen the connection between the dermis and the epidermis to increase the stability of the skin layers. Prior art literature

[0004] Republic of Korea Patent Publication No. 10-2014-0003198 The problem to be solved

[0005] The present disclosure aims to provide a composition that effectively improves skin sagging caused by damage to DEJ function due to aging by enhancing the binding strength between the epidermis and dermis and hardening the boundary between the epidermis and dermis through increasing the expression of Col7A1 and Col17A1, proteins that constitute the DEJ (dermoepidermal junction) connecting the epidermis and dermis, thereby strengthening the DEJ function. means of solving the problem

[0006] To achieve the above objective, one embodiment of the present invention provides a composition for improving skin sagging containing Compound K. Effects of the invention

[0007] The composition for improving skin sagging according to the present disclosure can effectively improve skin sagging caused by damage to DEJ function due to aging by increasing the expression of Col7A1 and Col17A1, which are proteins constituting the DEJ (dermoepidermal junction) connecting the epidermal layer and the dermal layer, thereby enhancing the DEJ function and improving the binding strength between the epidermal layer and the dermal layer and hardening the boundary between the epidermal layer and the dermal layer. Brief explanation of the drawing

[0008] Figure 1 shows the results of the skin cytotoxicity test of Compound K. Figures 2a and 2b show the results of confirming changes in the expression of Col7A1 and Col17A1 in an accelerated skin aging environment caused by UVB treatment. Figures 3a and 3b show the results of confirming changes in the expression of Col7A1 and Col17A1 in an accelerated skin aging environment caused by fine dust (PM2.5) treatment. Figures 4a and 4b show the results of confirming changes in the expression of Col7A1 and Col17A1 in an accelerated skin aging environment caused by blue light (HEV) treatment. Figure 5 shows the results of confirming the efficacy of Compound K against accelerated skin aging caused by UVB treatment in artificial skin. Specific details for implementing the invention

[0009] The present invention will be described in detail below.

[0010] In one aspect, the present invention may relate to a composition for improving skin sagging containing Compound K.

[0011] In one aspect, the present invention may relate to a method for improving skin sagging, comprising applying or administering an effective amount of Compound K to a subject who requires it.

[0012] In one aspect, the present invention may relate to the use of Compound K for preparing a composition for improving skin sagging.

[0013] In one aspect, the present invention may relate to Compound K for use in improving skin sagging.

[0014] In one aspect, the present invention may relate to a non-therapeutic use of Compound K for improving skin sagging.

[0015] 'Skin sagging' is a condition affected by gravity; preventing or improving sagging requires that the epidermal cells forming the epidermal layer be tightly stacked and that the epidermis and dermis be firmly connected. 'Skin elasticity' relates to the skin's resilience and is associated with collagen in the dermis. As such, skin sagging, which is directly linked to the function of the epidermal-dermal junction (DEJ), is distinct from skin elasticity.

[0016] Skin sagging and skin elasticity are both attributes associated with skin aging, but their definitions and mechanisms differ. Skin sagging primarily refers to the phenomenon where skin tissue droops downward due to the influence of gravity, and as aging progresses, the skin's supporting structures weaken, which can make the skin appear more saggy.

[0017] Skin elasticity refers to the skin's ability to return to its original shape after being stretched. This property is closely related to the quality and quantity of collagen and elastin fibers. When elasticity decreases, the skin stretches easily even without clear stimulation, which can lead to wrinkles and sagging. In other words, reduced skin elasticity makes sagging more likely to occur. On the other hand, skin sagging can be caused by complex factors, such as not only a decrease in elasticity but also changes in the skin's microstructure and the reduction or deformation of subcutaneous fat tissue.

[0018] The dermoepidermal junction (DEJ) is the connection site between the epidermis and dermis, playing a crucial role in the skin's structural integrity and function. The DEJ provides support to the epidermis and facilitates the transport of nutrients and metabolic products between the dermis and epidermis. Structural changes in the DEJ can significantly affect the appearance and degree of skin sagging. The DEJ contains DEJ-specific structural proteins such as COL7 and COL17, which contribute to the structural integrity of the DEJ. The decrease in DEJ constituent structural proteins due to aging weakens skin tension and leads to increased skin sagging. The DEJ structure is not flat but curved, a structure known as a rete ridge. Rete ridges increase the contact area between the epidermis and dermis and contribute to the bonding of the epidermal and dermal layers by dispersing the physical load applied to the epidermis. Rete ridges flatten with aging, and these structural changes in rete ridges induce a decrease in the bonding strength between the epidermis and dermis, leading to skin sagging. Additionally, it has been reported that changes in the expression of DEJ-specific structural proteins alter the structure of rete ridges, and there are reports that skin sagging improves when the expression of specific collagen proteins present in the DEJ is increased.

[0019] In one embodiment, the compound K can be represented by the following chemical formula 1.

[0020]

[0021] In one embodiment, the compound K may be contained in an amount of 0.0002 to 0.04 weight% relative to the total weight of the composition. Specifically, the compound K may be included in an amount of 0.0002 wt% or more, 0.0003 wt% or more, 0.0004 wt% or more, 0.0005 wt% or more, 0.0006 wt% or more, 0.0007 wt% or more, 0.0008 wt% or more, 0.0009 wt% or more, 0.001 wt% or more, 0.002 wt% or more, 0.003 wt% or more, 0.004 wt% or more, 0.005 wt% or more, 0.006 wt% or more, 0.007 wt% or more, 0.008 wt% or more, 0.009 wt% or more, 0.01 wt% or more, or 0.02 wt% or more, based on the total weight of the composition; additionally, the compound K may be included in an amount of 0.04 wt% or less, 0.03 wt% or less, based on the total weight of the composition. It may be included in an amount of 0.02 wt% or less, 0.01 wt% or less, 0.009 wt% or less, 0.008 wt% or less, 0.007 wt% or less, 0.006 wt% or less, 0.005 wt% or less, 0.004 wt% or less, 0.003 wt% or less, 0.002 wt% or less, 0.001 wt% or less, 0.0009 wt% or less, 0.0008 wt% or less, 0.0007 wt% or less, 0.0006 wt% or less, 0.0005 wt% or less, 0.0004 wt% or less, or 0.0003 wt% or less.

[0022] In one embodiment, the compound K can increase the expression of Col7A1.

[0023] In one embodiment, the compound K can increase the expression of Col17A1.

[0024] Col7A1 and Col17A1 are proteins that make up the dermoepidermal junction (DEJ). A decrease in Col7A1 and Col17A1 impairs the function of the DEJ, which firmly holds epidermal cells and strengthens the connection between the epidermal and dermal layers, thereby causing skin sagging.

[0025] In one embodiment, the compound K can enhance the DEJ (epidermal-dermal junction) function.

[0026] In one embodiment, the compound K can improve the bonding strength between the epidermal layer and the dermal layer.

[0027] In one embodiment, the compound K can enhance DEJ (epidermal-dermal junction) function by increasing the expression of one or more of Col7A1 and Col17A1.

[0028] In one embodiment, the compound K can improve the bonding strength between the epidermal layer and the dermal layer by increasing the expression of one or more of Col7A1 and Col17A1.

[0029] In one embodiment, the compound K can improve skin sagging by increasing the expression of at least one of Col7A1 and Col17A1, thereby strengthening the DEJ (epidermal-dermal junction) function, improving the bonding strength between the epidermal layer and the dermal layer, and firming the boundary between the epidermal layer and the dermal layer.

[0030] In one embodiment, the daily application amount of Compound K may be 0.5 mg / kg body weight to 10 mg / kg (body weight). Specifically, the daily application, application, or intake amount of the above Compound K is 0.5 mg / kg (body weight) or more, 1 mg / kg (body weight) or more, 1.5 mg / kg (body weight) or more, 2 mg / kg (body weight) or more, 2.5 mg / kg (body weight) or more, 3 mg / kg (body weight) or more, 3.5 mg / kg (body weight) or more, 4 mg / kg (body weight) or more, 4.5 mg / kg (body weight) or more, 5 mg / kg (body weight) or more, 5.5 mg / kg (body weight) or more, 6 mg / kg (body weight) or more, 6.5 mg / kg (body weight) or more, 7 mg / kg (body weight) or more, 7.5 mg / kg (body weight) or more, 8 mg / kg (body weight) or more, 8.5 mg / kg (body weight) or more, 9 mg / kg (body weight) or more, or 9.5 mg / kg (body weight). It may be more than, and additionally, the daily dosage of the above Compound K may be 10 mg / kg (body weight) or less, 9.5 mg / kg (body weight) or less, 9 mg / kg (body weight) or less, 8.5 mg / kg (body weight) or less, 8 mg / kg (body weight) or less, 7.5 mg / kg (body weight) or less, 7 mg / kg (body weight) or less, 6.5 mg / kg (body weight) or less, 6 mg / kg (body weight) or less, 5.5 mg / kg (body weight) or less, 5 mg / kg (body weight) or less, 4.5 mg / kg (body weight) or less, 4 mg / kg (body weight) or less, 3.5 mg / kg (body weight) or less, 3 mg / kg (body weight) or less, 2.5 mg / kg (body weight) or less, 2 mg / kg (body weight) or less, 1.5 mg / kg (body weight) or less, or 1 mg / kg (body weight) or less. there is.

[0031] In one embodiment, the composition may be a cosmetic composition.

[0032] The cosmetic composition according to one embodiment of the present invention may contain a cosmetically or dermatologically acceptable medium or base. This may be provided in any formulation suitable for topical application, for example, in the form of a solution, gel, solid, paste anhydrous product, emulsion obtained by dispersing an oil phase in an aqueous phase, suspension, microemulsion, microcapsule, microgranule, or ionic (liposome) and non-ionic vesicular dispersants, or in the form of a cream, skin, lotion, powder, ointment, spray, or concealer stick. These compositions may be prepared according to conventional methods in the art. The cosmetic composition may also be used in the form of an aerosol composition further containing a propellant compressed in the form of foam.

[0033] The above cosmetic composition is not particularly limited in its formulation and can be appropriately selected according to the purpose. For example, it may be manufactured in formulations such as skin lotion, skin softener, skin toner, lotion, milk lotion, moisture lotion, nourishing lotion, massage cream, nourishing cream, moisture cream, hand cream, foundation, essence, nourishing essence, pack, soap, cleansing foam, cleansing lotion, cleansing cream, cleansing water, powder, body lotion, body cream, body oil, body cleanser, and body essence.

[0034] In the case where the formulation of the above cosmetic composition is a paste, cream, or gel, animal fiber, plant fiber, wax, paraffin, starch, tracanth, cellulose derivative, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as a carrier component.

[0035] In the case where the formulation of the above cosmetic composition is a powder or a spray, lactose, talc, silica, aluminum hydroxide, calcium silicate, or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, it may additionally include a propellant such as chlorofluorohydrocarbon, propane / butane, or dimethyl ether.

[0036] In the case where the formulation of the above cosmetic composition is a solution or an emulsion, a solvent, a solvating agent, or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, or fatty acid ester of sorbitan.

[0037] In the case where the formulation of the above cosmetic composition is a suspension, liquid diluents such as water, ethanol, or propylene glycol, suspending agents such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester, and polyoxyethylene sorbitan ester, microcrystalline cellulose, aluminum metahydroxide, bentonite, agar, or tracanthenic acid may be used as carrier components.

[0038] In the case where the formulation of the above cosmetic composition is a cleansing product containing a surfactant, aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyl taurate, sarcosinate, fatty acid amide ether sulfate, alkylamidobetaine, aliphatic alcohol, fatty acid glyceride, fatty acid diethanolamide, vegetable oil, linolin derivative, or ethoxylated glycerol fatty acid ester, etc. may be used as a carrier component.

[0039] In addition to Compound K, the above cosmetic composition may further include functional additives and ingredients included in general cosmetic compositions. The above functional additives may include ingredients selected from the group consisting of water-soluble vitamins, oil-soluble vitamins, high molecular weight peptides, high molecular weight polysaccharides, sphingolipids, and seaweed extracts.

[0040] In addition to the functional additives, the above composition may also include ingredients included in general cosmetic compositions as needed. Other ingredients included may include oils, moisturizers, emollients, surfactants, organic and inorganic pigments, organic powders, UV absorbers, preservatives, disinfectants, antioxidants, plant extracts, pH adjusters, alcohols, colorants, fragrances, blood circulation promoters, cooling agents, antiperspirants, purified water, etc.

[0041] In one embodiment, the composition may be a non-therapeutic oral composition or a food composition.

[0042] The formulation of the above-mentioned non-therapeutic oral composition or food composition is not particularly limited, but may be formulated, for example, into tablets, granules, pills, powders, liquids such as drinks, caramels, gels, bars, tea bags, etc. For each formulation of the non-therapeutic oral composition or food composition, in addition to the active ingredient, ingredients commonly used in the relevant field can be appropriately selected and combined without difficulty by a person skilled in the art according to the formulation or purpose of use, and a synergistic effect may occur when applied simultaneously with other raw materials. The above-mentioned composition may be administered by various methods, such as simple ingestion, drinking, injection, spray administration, or squeeze administration.

[0043] In a non-therapeutic oral composition or food composition according to one embodiment of the present invention, the determination of the dosage or intake amount of the active ingredient is within the level of a person skilled in the art and may vary depending on various factors such as the age, health condition, and complications of the subject to be administered or consumed.

[0044] A non-therapeutic oral composition or food composition according to one embodiment of the present invention may be, for example, various food products such as chewing gum, caramel products, candies, frozen desserts, confectionery, etc., beverage products such as soft drinks, mineral water, alcoholic beverages, etc., or oral products containing vitamins or minerals.

[0045] In addition to the above, a non-therapeutic oral composition or food composition according to one embodiment of the present invention may include various nutritional supplements, vitamins, minerals (electrolytes), flavoring agents such as synthetic and natural flavoring agents, coloring agents and promoters (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used in carbonated beverages, etc. Furthermore, a non-therapeutic oral composition or food composition according to one embodiment of the present invention may include fruit pulp for the production of natural fruit juices, fruit juice beverages, and vegetable beverages. These ingredients may be used independently or in combination. Although the proportion of these additives is not particularly important, they are generally included in the range of 0 to about 60 parts by weight per 100 parts by weight of the composition according to one embodiment of the present invention.

[0047] As one embodiment, the present invention may provide the following embodiments.

[0048] The first embodiment may provide a composition for improving skin sagging containing Compound K.

[0049] A second embodiment may provide a composition in which, in the first embodiment, the compound K is contained in an amount of 0.0002 to 0.04 weight% relative to the total weight of the composition.

[0050] A third embodiment may provide a composition in which, in one or more of the first and second embodiments, the compound K increases the expression of Col7A1.

[0051] The fourth embodiment may provide a composition in which, in one or more of the first to third embodiments, the compound K increases the expression of Col17A1.

[0052] The fifth embodiment may provide a composition in which, in one or more of the first to fourth embodiments, the compound K improves the DEJ (dermodermal-dermal junction) function.

[0053] The sixth embodiment may provide a composition in which, in one or more of the first to fifth embodiments, the compound K improves the bonding strength between the epidermal layer and the dermal layer.

[0054] The seventh embodiment may provide a composition in which, in one or more of the first to sixth embodiments, the daily application amount of compound K is 0.5 mg / kg (body weight) to 10 mg / kg (body weight).

[0055] The eighth embodiment may provide a composition that is a cosmetic composition in one or more of the first to seventh embodiments.

[0056] The ninth embodiment may provide a composition that is a non-therapeutic oral composition in one or more of the first to eighth embodiments.

[0058] The contents of the present invention will be explained in more detail below through experimental examples. However, these experimental examples are presented merely to help understand the contents of the present invention, and the scope of the present invention is not limited to these experimental examples. Modifications, substitutions, and insertions commonly known in the art may be performed, and such are also included within the scope of the present invention.

[0060] [Experimental Example 1] Skin cell toxicity test

[0061] To confirm the cytotoxicity of Compound K against skin keratinocytes, 1 x 10⁶ human epidermal keratinocytes were placed in a 96-well plate. 4 Cells were seeded and cultured for 24 hours. Subsequently, cells were treated with Compound K at final concentrations per well of 0.5 ppm, 1 ppm, 2 ppm, and 4 ppm, respectively, and cultured for 24 hours. 10 μl of Cell Counting Kit-8 (CCK-8) solution was added to each well and incubated at 37°C for two hours, after which absorbance was measured at 450 nm. Cell proliferation and toxicity effects were calculated as percentages based on the absorbance of the control group. The results are shown in Figure 1.

[0062] From the results of Figure 1, it was confirmed that Compound K does not cause cytotoxicity at a concentration of 0.5 ppm to 4 ppm.

[0064] [Experimental Example 2] Experiment on Acceleration of Skin Aging

[0065] To confirm the acceleration of skin aging due to external stimuli, 1 x 10⁶ human epidermal keratinocytes were placed in a 96-well plate. 4 After seeding, the culture was incubated for 24 hours. Subsequently, an inflammatory response was induced by treating the medium with the inflammatory senescence factor IL-17A at a concentration of 50 μg / ml. After 24 hours, the culture medium was removed, replaced with PBS, and then subjected to ultraviolet (UVB) radiation at 20 mJ / cm². 2 Irradiating or treating with 100 μg / ml of fine dust (PM2.5) or 40 J / cm² of blue light (HEV) 2The cells were investigated, and after switching to a medium containing 50 μg / ml of IL-17A, they were cultured for an additional 24 hours. Subsequently, total RNA was extracted from skin keratinocytes using an RNA extraction kit (Quiagen, RNease Mini kit), and cDNA was synthesized from the extracted RNA (Invitrogen, SuperScript VILO Master Mix). Changes in the expression levels of Col7A1 and Col17A1 were then observed using a 7500 Fast Real-time PCR System (Thermo Fisher Scientific) and a Taqman probe (Applied Biosystems). The results are shown in Figures 2a and 2b (UV treatment), Figures 3a and 3b (fine dust treatment), and Figures 4a and 4b (blue light treatment).

[0066] From the results of Figures 2a and 2b, it was confirmed that the expression of Col7A1 and Col17A1 was significantly reduced in an accelerated aging environment treated with UVB after IL-17A treatment, compared to cases treated with only IL-17A or only ultraviolet (UVB) rays.

[0067] Likewise, from the results of Figures 3a and 3b and Figures 4a and 4b, it was confirmed that the expression of Col7A1 and Col17A1 was significantly reduced in an accelerated aging environment treated with PM2.5 or HEV after IL-17A treatment, compared to cases treated with only IL-17A or only fine dust (PM2.5) or blue light (HEV).

[0068] From the experimental results above, it was found that the expression of Col7A1 and Col17A1 decreased more significantly in environments where aging was accelerated by external stimuli (ultraviolet rays, fine dust, blue light) in addition to general aging.

[0069] It is known that a decrease in Col7A1 and Col17A1 weakens the DEJ structure and alters the rete ridge structure, thereby accelerating skin aging. Therefore, restoring the expression of reduced Col7A1 and Col17A1 can prevent and improve the alteration of the DEJ and rete ridge structures, thereby preventing and improving skin sagging.

[0071] [Experimental Example 3] Experiment to Confirm the Efficacy of Compound K at Different Concentrations on UV-Treated Aging Skin

[0072] To determine the efficacy of Compound K at different concentrations on UV-treated aging skin, human epidermal keratinocytes were placed in a 96-well plate at a concentration of 1 x 10⁶ 4 After seeding, the culture was incubated for 24 hours, and then Compound K was treated at concentrations of 0.5 ppm, 1 ppm, 2 ppm, and 4 ppm. After 30 minutes, IL-17A was additionally added to the medium at a concentration of 50 μg / ml; after 24 hours, the culture medium was removed, replaced with PBS, and then irradiated with ultraviolet (UVB) at 20 mJ / cm² 2 The cells were investigated and cultured for 24 hours. Subsequently, total RNA was extracted from skin keratinocytes using an RNA extraction kit (Quiagen, RNease Mini kit), and cDNA was synthesized from the extracted RNA (Invitrogen, SuperScript VILO Master Mix). Changes in the expression levels of Col7A1 and Col17A1 were then observed using a 7500 Fast Real-time PCR System (Thermo Fisher Scientific) and a Taqman probe (Applied Biosystems). The results are shown in Table 1 below.

[0073] stimulation Treatment concentration Col7A1 expression level (Fold) Col17A1 expression level (Fold) Control group (untreated) -(Non-irritating) - 1 1 Control group (untreated) IL-17A + UVB - 0.32 0.39 Compound K 0.5 ppm 0.32 0.40 1 ppm 0.34 0.45 2 ppm 1.39 1.17 4 ppm 1.21 1.09 EGCG 10 μM 0.38 0.66

[0074] From the results in Table 1, it was confirmed that when skin keratinocytes were pretreated with Compound K at concentrations of 1 ppm, 2 ppm, and 4 ppm, respectively, and then treated with IL-17A and UVB to accelerate aging, the reduced expression of Col7A1 and Col17A1 was restored. In particular, when treated at 2 ppm and 4 ppm, the effect of restoring Col7A1 and Col17A1 expression was significantly superior compared to the positive control, EGCG, and among them, the recovery rate of Col7A1 and Col17A1 expression was the best when treated at 2 ppm.

[0076] [Experimental Example 4] Experiment to Confirm the Efficacy of Compound K on Aging Skin Treated with Fine Dust

[0077] To confirm the efficacy of Compound K against aging caused by fine dust (PM2.5), human epidermal keratinocytes were placed in a 96-well plate at a rate of 1 x 10⁶ 4After seeding, the cells were cultured for 24 hours, followed by treatment with Compound K at a concentration of 2 ppm. Thirty minutes later, IL-17A was additionally added to the medium at a concentration of 50 μg / ml. After 24 hours, the culture medium was removed, replaced with PBS, and treated with 100 μg / ml of fine dust (PM2.5). The medium was then replaced with one containing 50 μg / ml of IL-17A and 2 ppm of Compound K, followed by an additional 24 hours of culture. Subsequently, total RNA was extracted from skin keratinocytes using an RNA extraction kit (Quiagen, RNease Mini kit), and cDNA was synthesized from the extracted RNA (Invitrogen, SuperScript VILO Master Mix). Changes in the expression levels of Col7A1 and Col17A1 were then observed using a 7500 Fast Real-time PCR System (Thermo Fisher Scientific) and a Taqman probe (Applied Biosystems). 10 μM of EGCG was used as a positive control. The results are shown in Table 2 below.

[0078] stimulation Col7A1 expression level (Fold) Col17A1 expression level (Fold) Control group (untreated) -(Non-irritating) 1 1 Control group (untreated) IL-17A + PM2.5 0.42 0.61 Compound K 0.64 0.80 EGCG 0.71 0.73

[0079] From the results in Table 2, it was confirmed that when skin keratinocytes were pretreated with 2 ppm of Compound K followed by treatment with IL-17A and PM2.5 to induce accelerated skin aging, Compound K significantly inhibited the decrease in expression of Col7A1 and Col17A1, which was similar to or even much superior to the effect of the positive control, EGCG.

[0081] [Experimental Example 5] Experiment to Confirm the Efficacy of Compound K on Aging Skin Treated with Blue Light

[0082] To confirm the efficacy of Compound K against aging induced by HEV light, human epidermal keratinocytes were placed in a 96-well plate at a rate of 1 x 10⁶ 4After seeding, the medium was incubated for 24 hours, followed by treatment with Compound K at a concentration of 2 ppm. After 30 minutes, IL-17A was additionally added to the medium at a concentration of 50 μg / ml; after 24 hours, the culture medium was removed, replaced with PBS, and then subjected to blue light (HEV) of 40 J / cm² 2 The cells were investigated, and after switching to a medium containing 50 μg / ml of IL-17A and 2 ppm of Compound K, they were cultured for an additional 24 hours. Subsequently, total RNA was extracted from skin keratinocytes using an RNA extraction kit (Quiagen, RNease Mini kit), and cDNA was synthesized from the extracted RNA (Invitrogen, SuperScript VILO Master Mix). Changes in the expression levels of Col7A1 and Col17A1 were then observed using a 7500 Fast Real-time PCR System (Thermo Fisher Scientific) and a Taqman probe (Applied Biosystems). 10 μM of EGCG was used as a positive control. The results are shown in Table 3 below.

[0083] stimulation Col7A1 expression level (Fold) Col17A1 expression level (Fold) Control group (untreated) -(Non-irritating) 1 1 Control group (untreated) IL-17A + HEV 0.39 0.73 Compound K 0.58 0.90 EGCG 0.62 0.89

[0084] From the results in Table 3, it was confirmed that when skin keratinocytes were pretreated with 2 ppm of Compound K followed by treatment with IL-17A and HEV to induce accelerated skin aging, Compound K significantly inhibited the decrease in expression of Col7A1 and Col17A1, which was similar to or even much superior to the effect of the positive control, EGCG.

[0086] [Experimental Example 6] Experiment to Confirm the Efficacy of Compound K on Ultraviolet-Treated Aged Artificial Skin

[0087] To confirm the efficacy of Compound K on UV-treated aged artificial skin, Compound K was applied to the culture medium of an artificial skin epidermal model (MatTek Life Science) at a concentration of 2 ppm. After 30 minutes, IL-17A was additionally applied to the medium at a concentration of 100 μg / ml; after 24 hours, the culture medium was removed, replaced with PBS, and then subjected to ultraviolet (UVB, Bio-Sun, Viber) 100 mJ / cm² 2 The sample was investigated, replaced with a medium containing 100 μg / ml of IL-17A and 2 ppm of Compound K, and cultured for an additional 48 hours. Subsequently, a paraffin block was prepared as an artificial skin tissue, and the amount of Col17A1 was measured by staining it with an antibody (Abcam). The results are shown in Figure 5 (Blue: DAPI (nuclear staining), Green: Col17A1).

[0088] From the results of Figure 5, it was confirmed that when artificial skin epidermal tissue was pretreated with Compound K and then treated with IL-17A and UVB to accelerate aging, the reduced expression of Col17A1 was significantly restored.

[0090] From the experimental results above, it was found that Compound K effectively inhibits the decrease in expression of Col7A1 and Col17A1 in an environment where aging is accelerated by external stimuli (UV rays, fine dust, blue light) in addition to general aging. Through this, it can be seen that Compound K can effectively improve skin sagging caused by age-related DEJ function impairment by strengthening DEJ (epidermal-dermal junction) function, improving the bonding strength between the epidermal and dermal layers, and solidifying the boundary between the two layers.

[0092] [Formulation Example 1] Lotion

[0093] ingredient Content (Weight) Compound K 0.03 L-ascorbic acid-2-magnesium phosphate 1.00 Water-soluble collagen (1% aqueous solution) 1.00 Sodium citrate 0.10 citric acid 0.05 Licorice extract 0.20 1,3-Butylene Glycol 3.00 purified water Remaining amount

[0094] [Formulation Example 2] Cream

[0095] ingredient Content (Weight) Compound K 0.03 polyethylene glycol monostearate 2.00 glycerin 5.00 Cetyl alcohol 4.00 Squalene 4.00 Liquid paraffin 10.00 Tri-2-ethylhexaneglyceryl 6.00 sphingoglycolipid 1.00 1,3-Butylene Glycol 7.00 purified water Remaining amount

[0096] [Formulation Example 3] Pack

[0097] ingredient Content (Weight) Compound K 0.03 Polyvinyl alcohol 13.00 L-ascorbic acid-2-magnesium phosphate 1.00 Lauroylhydroxyproline 1.00 Water-soluble collagen (1% aqueous solution) 2.00 1,3-Butylene Glycol 3.00 ethanol 5.00 purified water Remaining amount

[0098] [Formulation Example 4] Lotion

[0099] ingredient Content (Weight) Compound K 0.03 glycerin 3.0 Butylene glycol 2.0 Propylene glycol 2.0 Carboxyvinyl polymer 0.1 PEG-12 nonylphenyl ether 0.2 Polysorbate-80 0.4 ethanol 10.0 Triethanolamine 0.1 Preservatives, colorings, fragrances Appropriate amount purified water Remaining amount

[0100] Foregoing, specific parts of this specification have been described in detail. It is evident to those skilled in the art that such specific descriptions are merely preferred embodiments and that the scope of this specification is not limited thereto. Accordingly, the actual scope of this specification shall be defined by the appended claims and their equivalents.

Claims

Claim 1 A composition for improving skin sagging, comprising Compound K, wherein the skin sagging is caused by (i) impairment of DEJ (dermodermal junction) function or (ii) at least one of UVB, fine dust, and blue light, and wherein Compound K improves skin sagging by increasing the expression of Col7A1 and Col17A1. Claim 2 A composition according to claim 1, wherein the compound K is contained in an amount of 0.0002 to 0.04 weight% relative to the total weight of the composition. Claim 3 delete Claim 4 delete Claim 5 In claim 1, the above compound K is a composition that enhances DEJ (dermodermal-dermal junction) function. Claim 6 In claim 1, the above compound K is a composition that improves the bonding strength between the epidermal layer and the dermal layer. Claim 7 A composition according to claim 1, wherein the daily application amount of Compound K is 0.5 mg / kg (body weight) to 10 mg / kg (body weight). Claim 8 A composition that is a cosmetic composition in any one of paragraphs 1, 2, 5 through 7. Claim 9 A composition that is a non-therapeutic oral composition in any one of claims 1, 2, 5 to 7.